Unknown

Dataset Information

0

Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach.

ABSTRACT:

SUBMITTER: Jassem J 

PROVIDER: S-EPMC6987370 | biostudies-literature | 2019 Dec

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Adjuvant EGFR tyrosine kinase inhibitors in <i>EGFR</i>-mutant non-small cell lung cancer: still an investigational approach.

Jassem Jacek J  

Translational lung cancer research 20191201 Suppl 4

Similar Datasets

Unknown Use of adjuvant EGFR tyrosine kinase inhibitors in early stage <i>EGFR</i>-mutant non-small cell lung cancer: is the evidence strong enough?
| S-EPMC7578493 | biostudies-literature
Unknown Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis.
| S-EPMC5599620 | biostudies-literature
Unknown Remodeling of tumor microenvironments by EGFR tyrosine kinase inhibitors in <i>EGFR</i>-mutant non-small cell lung cancer.
| S-EPMC11787596 | biostudies-literature
Unknown JAK2 inhibition sensitizes resistant EGFR-mutant lung adenocarcinoma to tyrosine kinase inhibitors.
| S-EPMC4950506 | biostudies-literature
Unknown MUC3A induces PD-L1 and reduces tyrosine kinase inhibitors effects in EGFR-mutant non-small cell lung cancer.
| S-EPMC8120466 | biostudies-literature
Unknown Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors.
| S-EPMC6925200 | biostudies-literature
Unknown The Presence of Concomitant Mutations Affects the Activity of EGFR Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) Patients.
| S-EPMC6468673 | biostudies-literature
Unknown Prediction Model for Tumor Volume Nadir in EGFR -mutant NSCLC Patients Treated With EGFR Tyrosine Kinase Inhibitors.
| S-EPMC8920948 | biostudies-literature
Unknown Improved survival in patients with unresectable stage III EGFR-mutant adenocarcinoma with upfront EGFR-tyrosine kinase inhibitors.
| S-EPMC8758433 | biostudies-literature
Unknown First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors.
| S-EPMC3459550 | biostudies-literature